Peter Junker

MRI bone oedema is the strongest predictor of subsequent radiographic progression in early rheumatoid arthritis. Results from a 2-year randomised controlled trial (CIMESTRA)

Merete Lund Hetland, B Ejbjerg, Kim Hørslev‐Petersen et al. · Annals of the Rheumatic Diseases · 2008 · 364 citations

Radiographic progression and remission rates in early rheumatoid arthritis – MRI bone oedema and anti-CCP predicted radiographic progression in the 5-year extension of the double-blind randomised CIMESTRA trial

Merete Lund Hetland, K. Stengaard‐Pedersen, Peter Junker et al. · Annals of the Rheumatic Diseases · 2010 · 188 citations · Full text

Combination treatment with methotrexate, cyclosporine, and intraarticular betamethasone compared with methotrexate and intraarticular betamethasone in early active rheumatoid arthritis: An investigator‐initiated, multicenter, randomized, double‐blind, parallel‐group, placebo‐controlled study

Merete Lund Hetland, Kristian Stengaard‐Pedersen, Peter Junker et al. · Arthritis & Rheumatism · 2006 · 172 citations

A multicentre study of 513 Danish patients with systemic lupus erythematosus. I. Disease manifestations and analyses of clinical subsets

Søren Jacobsen, Jørgen Holm Petersen, Susanne Ullman et al. · Clinical Rheumatology · 1998 · 156 citations

Rheumatology, Clinical Finding, Autoimmune Disease +12

HLA‐G genotype and HLA‐G expression in systemic lupus erythematosus: HLA‐G as a putative susceptibility gene in systemic lupus erythematosus

Roberta Rizzo, Thomas Vauvert F. Hviid, Marcello Govoni et al. · Tissue Antigens · 2008 · 126 citations